Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London Harley Street Proton Therapy Centre

28 Jan 2015 07:00

RNS Number : 3041D
Advanced Oncotherapy PLC
28 January 2015
 



28 January 2015

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

London Harley Street Proton Therapy Centre

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for treating cancer, announces that it has signed an agreement to lease a prestigious Harley Street location, which will become the UK's first Proton Therapy Centre using the Company's LIGHT System.

 

The centre will become a hub where patients from London, the rest of the UK and others further afield can have their cancers effectively treated with a leading-edge proton therapy system.

 

Advanced Oncotherapy has signed an agreement with Howard de Walden Estates Limited ("Howard de Walden Estates") granting a 50 year lease for the whole of 141 Harley Street and part of 143 Harley Street to the Company. The properties, which comprise approximately 8,000 sq ft, will be converted for use as a Proton Therapy Centre, and will house the first LIGHT machine to be constructed and operated in the UK.

 

The grant of the lease is subject to the relevant planning and other statutory consents being obtained for the redevelopment of the buildings. The total cost of the redevelopment will be borne by Howard de Walden Estates and is estimated at between £6-7 million. Work will start in July 2015, with the property expected to be handed over to Advanced Oncotherapy by the end of 2016 when the first LIGHT System will be ready, enabling patients to start treatments in 2017.

 

The Company also has an agreement with SUNY Upstate Medical University Hospital in Syracuse, Central New York State to build a US based proton therapy facility using the LIGHT system. The facility in Harley Street will be constructed in parallel with the US installation, and the Company is in early discussions with private healthcare providers in the UK to operate in this prestigious location.

Sanjeev Pandya, CEO of Advanced Oncotherapy, commented: "This is the first step in bringing the very latest in proton beam therapy to the UK and right into the heart of London. We are putting a proton system into 2 standard row houses, something that simply would not be possible with any of the existing proton systems that are currently operational. Having a facility in central London will make proton therapy accessible to many cancer sufferers in the UK and others from abroad. I would also like to add that I am delighted that this first UK Centre will be in Harley Street, without doubt one of the most prestigious medical addresses in the world."

 

Simon Baynham, Property Director at Howard de Walden Estates, said: "The Harley Street Medical Area is a unique concentration of medical excellence which is unrivalled on a global basis. The Estate has been investing significantly in the medical area over the last 10 years or so, to ensure that the facilities in and around Harley Street continue to provide suitable medical buildings. Over the last 9 months, we have been working collaboratively with Advanced Oncotherapy to find a suitable location within the Harley Street area, for a LIGHT Proton Beam Therapy unit. We are delighted that a location has been found, and subject to planning, our intention is to start work on providing this bespoke facility as soon as possible.

 

It is hoped that the Proton Beam Therapy unit will be the first such centre to open in the UK, which can be used in the better treatment of all cancers which would ordinarily be treated with radiotherapy. Ideally, we would not ordinarily want to be the first, but to learn from others. However, the benefits of Proton Beam Therapy will undoubtedly save lives, and having visited the research facilities in CERN, we are in no doubt that this technology can be designed, built and installed in one of our standard period buildings.

 

We are therefore extremely excited that such a ground breaking and pioneering new facility is to be built in Harley Street, based upon advances and research carried out at CERN. Such a facility should further enhance the tremendous work already being carried out in Harley Street, by some of the world's top oncologists and radiologists in the field of cancer."

 

Nick Plowman, Senior Clinical Oncologist to St Bartholomew's Hospital & Great Ormond Street Hospital, commented: "Proton beam radiotherapy is the radiotherapy of the future. Collateral damage to adjacent normal body tissues is minimised by this form of radiation therapy. The next generation 'LIGHT' protons look to supplant current generation technology. It is great news for UK patients that London will spearhead this advance."

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

Beaufort Securities (Joint Broker)

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy using protons.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRPKODKOBKDNDB
Date   Source Headline
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.